Transport
ST. Luke's Magic Valley Regional Medical Center, LTD.
ST. Luke's Magic Valley Regional Medical Center, LTD. was paid $7.95M by Medicaid between Jan 2018 and Dec 2024, across 320 billing codes. Its largest line is 92507, Treatment of speech, language, voice, communication, and/or auditory processing disorder — 10% of everything it billed.
33Billing provider infoST. LUKE'S MAGIC VALLEY REGIONAL MEDICAL CENTER, LTD.
TWIN FALLS, ID 83301
TWIN FALLS, ID 83301
33aNPI1932154705assigned 05/23/2006
33bProvider typeAir Ambulance
28Total paid$7.95M
24GClaims576,604
24DCodes billed320
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FOWLER, KATHRYN controls 18+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 182,703 | $2.89M | |
| 2019 | 184,049 | $3.09M | |
| 2020 | 107,493 | $1.60M | |
| 2021 | 26,476 | $114K | |
| 2022 | 31,022 | $128K | |
| 2023 | 29,842 | $84K | |
| 2024incomplete | 15,019 | $41K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 10% | 13,463 | 4,418 | $804K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 8.8% | 363 | 353 | $701K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 6.8% | 58,972 | 38,663 | $542K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 5.8% | 7,075 | 2,602 | $464K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.4% | 2,580 | 2,431 | $353K |
| 41899 | Unlisted procedure, dentoalveolar structures | 3.8% | 314 | 304 | $304K |
| 80053 | Comprehensive metabolic panel | 2.1% | 27,564 | 22,820 | $163K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.0% | 37,074 | 28,061 | $157K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.9% | 2,553 | 2,336 | $147K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 1.8% | 154 | 154 | $145K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.7% | 3,897 | 1,416 | $131K |
| 92526 | 1.4% | 1,834 | 785 | $111K |
308 more codes
| 99284 | Emergency room visit (serious) | 1.4% | 2,791 | $109K |
| 92523 | 1.3% | 682 | $105K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.3% | 2,905 | $104K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.2% | 2,871 | $99K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 1.2% | 1,324 | $94K |
| 99283 | Emergency room visit (moderate) | 1.2% | 2,875 | $92K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 1,831 | $90K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.1% | 5,250 | $89K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.1% | 415 | $88K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.0% | 2,068 | $81K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.0% | 7,303 | $81K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,868 | $79K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,325 | $74K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,220 | $71K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 623 | $69K |
| 36415 | Collection of venous blood by venipuncture | <1% | 43,718 | $63K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,340 | $61K |
| 99285 | Emergency room visit (most serious) | <1% | 1,152 | $60K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,496 | $57K |
| 87430 | <1% | 3,841 | $54K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 398 | $53K |
| 76830 | Ultrasound, transvaginal | <1% | 828 | $51K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 600 | $49K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 683 | $46K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 386 | $43K |
| G0378 | Hospital observation service, per hour | <1% | 1,138 | $42K |
| 83880 | <1% | 3,084 | $40K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,016 | $39K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 931 | $38K |
| 81001 | <1% | 16,167 | $37K | |
| 87081 | <1% | 5,401 | $37K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,927 | $36K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 849 | $36K |
| 80061 | Lipid panel | <1% | 4,554 | $35K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,818 | $33K |
| 97162 | <1% | 799 | $31K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,948 | $31K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,133 | $30K |
| 86140 | <1% | 10,116 | $29K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 254 | $28K |
| 87506 | <1% | 150 | $27K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 187 | $27K |
| 81025 | <1% | 4,015 | $27K | |
| 83690 | <1% | 5,818 | $27K | |
| 84484 | <1% | 5,455 | $26K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 756 | $26K |
| 87420 | <1% | 1,921 | $25K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,289 | $25K |
| 87077 | <1% | 3,875 | $24K | |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | <1% | 478 | $24K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 531 | $23K |
| 73610 | <1% | 1,501 | $22K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 309 | $22K |
| 73110 | <1% | 1,238 | $22K | |
| 84702 | <1% | 1,406 | $22K | |
| 73630 | <1% | 1,569 | $21K | |
| 83605 | <1% | 3,360 | $20K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 778 | $20K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 355 | $20K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 126 | $19K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 11,305 | $19K |
| 73140 | <1% | 1,032 | $18K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,794 | $18K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 313 | $18K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 640 | $18K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,125 | $17K |
| 80306 | <1% | 1,313 | $17K | |
| 73130 | <1% | 1,077 | $17K | |
| 97116 | <1% | 977 | $16K | |
| 87040 | <1% | 1,828 | $16K | |
| 84439 | <1% | 2,021 | $16K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 452 | $15K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 78 | $15K |
| 74018 | <1% | 1,138 | $15K | |
| 87186 | <1% | 2,426 | $14K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 156 | $14K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 575 | $14K |
| 83970 | <1% | 609 | $14K | |
| 82962 | <1% | 8,652 | $14K | |
| 82803 | <1% | 881 | $14K | |
| 87505 | <1% | 123 | $14K | |
| 86762 | <1% | 1,049 | $14K | |
| 84145 | <1% | 1,182 | $13K | |
| J2704 | Injection, propofol, 10 mg | <1% | 7,327 | $13K |
| 72100 | <1% | 949 | $13K | |
| 87340 | <1% | 1,347 | $13K | |
| 73564 | <1% | 706 | $12K | |
| 73562 | <1% | 889 | $12K | |
| 86850 | <1% | 1,807 | $12K | |
| 86703 | <1% | 927 | $12K | |
| 73502 | <1% | 788 | $12K | |
| 73030 | <1% | 1,142 | $12K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,813 | $12K |
| 36416 | <1% | 3,826 | $11K | |
| 85610 | <1% | 6,970 | $11K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 442 | $11K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 394 | $11K |
| 97166 | <1% | 212 | $10K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,383 | $10K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,513 | $10K |
| 74022 | <1% | 529 | $9K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 168 | $9K |
| 87641 | <1% | 437 | $9K | |
| 87640 | <1% | 436 | $9K | |
| 64483 | <1% | 28 | $9K | |
| 76942 | <1% | 664 | $8K | |
| 82728 | <1% | 776 | $8K | |
| 83516 | <1% | 669 | $8K | |
| 85379 | <1% | 1,063 | $8K | |
| 86803 | <1% | 792 | $8K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 104 | $8K |
| 87070 | <1% | 1,000 | $7K | |
| 72141 | <1% | 82 | $7K | |
| 87210 | <1% | 1,481 | $7K | |
| 73080 | <1% | 437 | $7K | |
| 71250 | <1% | 124 | $7K | |
| 92610 | <1% | 130 | $7K | |
| 87511 | <1% | 182 | $6K | |
| 87481 | <1% | 182 | $6K | |
| 72040 | <1% | 499 | $6K | |
| J3490 | Unclassified drugs | <1% | 323 | $6K |
| 81003 | <1% | 2,818 | $6K | |
| 73100 | <1% | 397 | $6K | |
| 86593 | <1% | 1,407 | $6K | |
| 83655 | <1% | 527 | $6K | |
| 84481 | <1% | 487 | $6K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,930 | $6K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 102 | $6K |
| S9470 | Nutritional counseling, dietitian visit | <1% | 307 | $6K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 857 | $6K |
| 82607 | <1% | 652 | $6K | |
| 97161 | <1% | 100 | $6K | |
| 87660 | <1% | 251 | $6K | |
| 86901 | <1% | 1,909 | $5K | |
| 83735 | <1% | 2,104 | $5K | |
| 73590 | <1% | 391 | $5K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,651 | $5K |
| 86900 | <1% | 1,825 | $5K | |
| 83550 | <1% | 806 | $5K | |
| 87205 | <1% | 1,460 | $5K | |
| 82950 | <1% | 1,089 | $5K | |
| 73090 | <1% | 391 | $5K | |
| 85730 | <1% | 1,232 | $5K | |
| 76642 | <1% | 147 | $5K | |
| 82570 | <1% | 2,210 | $5K | |
| 80074 | <1% | 97 | $5K | |
| 85652 | <1% | 2,963 | $5K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 57 | $4K |
| 87480 | <1% | 251 | $4K | |
| 87510 | <1% | 251 | $4K | |
| 83540 | <1% | 944 | $4K | |
| 85018 | <1% | 2,397 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,085 | $4K |
| 78227 | <1% | 12 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,046 | $4K |
| 82784 | <1% | 362 | $4K | |
| 82550 | <1% | 827 | $4K | |
| 82043 | <1% | 1,561 | $4K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,975 | $4K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 59 | $4K |
| 82247 | <1% | 666 | $4K | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 1,814 | $4K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 41 | $4K |
| 87449 | <1% | 417 | $3K | |
| 84703 | <1% | 454 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 501 | $3K |
| 70486 | <1% | 47 | $3K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 57 | $3K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 217 | $3K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,172 | $3K |
| 86376 | <1% | 232 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,351 | $3K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,475 | $3K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,627 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,162 | $3K |
| 74019 | <1% | 176 | $3K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 287 | $3K |
| 87324 | <1% | 336 | $3K | |
| 80069 | <1% | 473 | $3K | |
| G0008 | Administration of influenza virus vaccine | <1% | 1,718 | $2K |
| 97597 | <1% | 162 | $2K | |
| 90715 | <1% | 244 | $2K | |
| 86235 | <1% | 26 | $2K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 158 | $2K |
| 20610 | <1% | 650 | $2K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 986 | $2K |
| 82565 | <1% | 584 | $2K | |
| 80076 | <1% | 312 | $2K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 6,168 | $2K |
| 74230 | <1% | 44 | $2K | |
| 72110 | <1% | 104 | $2K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 12 | $2K |
| 82746 | <1% | 198 | $2K | |
| 76775 | <1% | 112 | $2K | |
| 92611 | <1% | 41 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,791 | $2K |
| 73560 | <1% | 135 | $2K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 14 | $2K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 68 | $2K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 450 | $2K |
| 76536 | <1% | 27 | $2K | |
| 87522 | Neg quan hep c or qual rna | <1% | 51 | $2K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 130 | $2K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 705 | $2K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 62 | $2K |
| 70496 | <1% | 14 | $2K | |
| 77002 | <1% | 47 | $1K | |
| 70498 | <1% | 17 | $1K | |
| 84100 | <1% | 790 | $1K | |
| 86706 | <1% | 157 | $1K | |
| 82140 | <1% | 149 | $1K | |
| 73070 | <1% | 82 | $1K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 93 | $1K |
| 76770 | <1% | 25 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,053 | $1K |
| 85014 | <1% | 689 | $1K | |
| 84550 | <1% | 386 | $1K | |
| 86038 | <1% | 153 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 289 | $1K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 656 | $1K |
| 82105 | <1% | 123 | $981.47 | |
| 84156 | <1% | 429 | $936.87 | |
| 77080 | <1% | 115 | $928.47 | |
| 84146 | <1% | 56 | $926.86 | |
| 80164 | <1% | 113 | $893.98 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 27 | $891.36 |
| 77066 | Tomosynthesis, mammo | <1% | 15 | $862.36 |
| 83520 | <1% | 77 | $847.12 | |
| 87338 | <1% | 53 | $814.98 | |
| 71101 | <1% | 61 | $813.15 | |
| 94060 | <1% | 44 | $778.69 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 105 | $737.05 |
| 84403 | <1% | 38 | $733.91 | |
| 72070 | <1% | 45 | $703.44 | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 12 | $681.00 |
| 86431 | <1% | 134 | $674.79 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 369 | $673.68 |
| 90686 | <1% | 399 | $670.52 | |
| 76801 | <1% | 12 | $670.15 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,166 | $659.78 |
| J1815 | Injection, insulin, per 5 units | <1% | 307 | $627.97 |
| 97168 | <1% | 13 | $581.02 | |
| 86200 | <1% | 46 | $532.05 | |
| 90662 | <1% | 474 | $529.41 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 933 | $520.27 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 747 | $502.75 |
| 82010 | <1% | 60 | $467.47 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,535 | $460.38 |
| 86480 | <1% | 13 | $450.95 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 2,058 | $416.06 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 730 | $415.95 |
| 86039 | <1% | 38 | $410.17 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 103 | $366.45 |
| 11721 | <1% | 133 | $358.15 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 71 | $346.67 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 843 | $309.84 |
| G0009 | Administration of pneumococcal vaccine | <1% | 266 | $308.06 |
| 81002 | <1% | 94 | $271.15 | |
| 86160 | <1% | 13 | $265.07 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 50 | $256.48 |
| 84305 | <1% | 13 | $245.31 | |
| 84153 | <1% | 13 | $245.28 | |
| 73000 | <1% | 18 | $239.25 | |
| 86308 | <1% | 40 | $215.83 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 985 | $215.27 |
| 51798 | <1% | 271 | $207.75 | |
| 90656 | <1% | 208 | $196.95 | |
| 93971 | <1% | 16 | $183.81 | |
| 87425 | <1% | 12 | $159.85 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 316 | $158.86 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 20 | $157.89 |
| 86255 | <1% | 13 | $147.29 | |
| 96376 | <1% | 620 | $141.57 | |
| 80178 | <1% | 16 | $110.10 | |
| 84165 | <1% | 13 | $107.92 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 220 | $102.51 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 699 | $100.00 |
| 83721 | <1% | 12 | $95.40 | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 24 | $94.80 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 15 | $93.29 |
| 94761 | <1% | 221 | $91.84 | |
| 90670 | <1% | 32 | $87.62 | |
| 82310 | <1% | 16 | $64.95 | |
| 80050 | General health panel | <1% | 193 | $41.43 |
| 84460 | <1% | 13 | $39.24 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 75 | $35.39 |
| 90732 | <1% | 14 | $32.42 | |
| 91320 | <1% | 46 | $21.04 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 19 | $17.10 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 853 | $10.93 |
| A9270 | Non-covered item or service | <1% | 5,281 | $2.49 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 44 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 352 | $0.00 |
| 90480 | 0% | 46 | $0.00 | |
| C1769 | Guide wire | 0% | 39 | $0.00 |
| 99406 | 0% | 35 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 42 | $0.00 |
| 0094A | 0% | 35 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 229 | $0.00 |
| 94726 | 0% | 12 | $0.00 | |
| 0124A | 0% | 17 | $0.00 | |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | 0% | 1,602 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 356 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 219 | $0.00 |
| S4990 | Nicotine patches, legend | 0% | 51 | $0.00 |
| 88312 | 0% | 69 | $0.00 | |
| 94729 | 0% | 27 | $0.00 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 33 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFOWLER, KATHRYN (SENIOR VP, CFO)
Parent organizationST LUKES HEALTH SYSTEM LTD
| Provider | Location | Paid |
|---|---|---|
| ST Lukes Clinic-Treasure Valley LLC | Boise, ID | $59.26M |
| ST Luke's Clinic LLC | Twin Falls, ID | $39.50M |
| ST Lukes Regional Medical Center | Boise, ID | $24.98M |
| ST Lukes Clinic-Treasure Valley LLC | Mountain Home, ID | $6.86M |
| Magic Valley Paramedics L L C | Twin Falls, ID | $4.57M |
| ST Lukes Clinic-Treasure Valley LLC | Baker City, OR | $2.08M |
| ST Lukes Nampa Medical Center LTD | Nampa, ID | $1.87M |
| ST Luke's Regional Medical Center | Meridian, ID | $1.55M |
| ST Lukes Regional Medical Center | Mountain Home, ID | $942K |
| ST Lukes Clinic - Wood River LLC | Ketchum, ID | $717K |
| ST Luke's Magic Valley Regional Medical Center LTD | Jerome, ID | $577K |
| ST Lukes Clinic - Mccall LLC | Mccall, ID | $576K |
| ST Luke's Regional Medical Center | Meridian, ID | $397K |
| ST. Luke's Magic Valley Regional Medical Center LTD | Twin Falls, ID | $300K |
| ST Lukes Wood River Medical Center LTD | Ketchum, ID | $174K |
| ST Lukes Mccall LTD | Mccall, ID | $149K |
| ST Lukes Regional Medical Center | Boise, ID | $49K |
| ST Lukes Magic Valley Regional Medical Center LTD | Twin Falls, ID | $11K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.